ChemoCentryx (CCXI) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to ChemoCentryx (CCXI) Reports In-Line Q4 EPS

ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

March 1, 2022 4:05 PM EST

-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis --

-- TAVNEOS also approved in European Union (EU) triggering $45 million milestone from Vifor Pharma received in Q1 2022 --

-- Company plans to initiate clinical development for TAVNEOS in lupus nephritis (LN) and to meet with FDA on the path forward in severe hidradenitis suppurativa (HS) and C3 glomerulopathy (C3G) in 2022 --

... More